[Drug-induced lung disease in general practice]

Area of Science:

• Pulmonology
• Pharmacology
• Toxicology

Context:

• Adverse medical side effects represent a significant cause of morbidity and mortality.
• The lungs, a complex organ system, are frequently implicated in drug-induced pathologies.
• Drug-induced pulmonary disease is a critical diagnostic challenge in clinical practice.

Purpose:

• To highlight the spectrum of lung injuries caused by medications.
• To identify common drug culprits and their associated clinical presentations.
• To emphasize the diagnostic approach and management of drug-induced pulmonary disease.

Summary:

• Adverse drug reactions manifest in the airways as cough, bronchospasms, and edema, and in the pulmonary parenchyma, leading to interstitial lung diseases (e.g., usual interstitial pneumonia, non-specific interstitial pneumonia, pulmonary edema, eosinophilic lung disease).
• Specific drugs like amiodarone and methotrexate are frequently associated with distinct pulmonary syndromes.
• The pleura, lung vasculature, and thoracic wall can also be affected.
• Drug-induced pulmonary disease is diagnosed by exclusion, with cessation of the causative agent being the cornerstone of therapy.
• Online resources like www.pneumotox.com aid clinicians in identifying and managing these conditions.

Impact:

• Enhances clinical recognition of drug-induced lung diseases.
• Facilitates timely diagnosis and intervention, potentially reducing patient morbidity and mortality.
• Provides a valuable resource for healthcare professionals managing complex pulmonary cases.